Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 5

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

Search:
in the keywords:  chemerin
help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Content available remote

Chemerin and the recruitment of NK cells to diseased skin*

100%
Skrzeczyńska-Moncznik J., Stefańska A., Zabel B. A., Kapińska-Mrowiecka M., Butcher E. C., Cichy J.
|
|
issue 2
355-360
EN
Natural killer (NK) cells play a major role in the initial control of many viral pathogens and in the rejection of tumors. Consistent with their roles as immune sentinels, NK cells are found in inflamed skin, including lichen planus, psoriasis and atopic dermatitis (AD) lesions. In oral lichen planus lesions, the recruitment as well as intradermal colocalization of NK cells and pDC (plasmacytoid dendritic cells) appear to be mediated by chemerin, a recently identified protein ligand for chemokine-like receptor 1 (CMKLR1), a chemoattractant receptor expressed by both cell types. Dendritic cells can regulate NK cell activity, and NK cells can regulate DC-mediated responses. Since chemerin was recently implicated in recruitment of pDC to psoriatic skin, in this work we determined whether chemerin facilitates interactions between NK and pDC in psoriatic plaques through controlling influx of NK cells to diseased skin. We demonstrate that circulating NK cells from normal donors as well as psoriasis and AD patients respond similarly in functional migration assays to chemerin. However, differences in the distribution of NK cells and pDC in skin lesions suggest that recruitment of both NK cells and pDC is unlikely to be controlled solely by chemerin.
2
Content available remote

Study of the Correlation between the Level of CRP and Chemerin of Serum and the Occurrence and Development of DN

100%
Wang Y., Wang M., Chen B., Shi J.
Open Medicine
|
2014
|
vol. 10
|
issue 1
EN
The aim of the study was to find the correlation between CRP and chemerin in development of DN. We choose 90 type-2 diabetic patients between February 2010 and February 2013, who were then divided into DN group and healthy control group. The results of BP showed that there is no difference in SBP and DBP of patients in the three groups. HDL-C of patients in diabetic group and DN group is lower compared with control. CRP in diabetic group and DN group is higher than that of patients in control group. Comparing the patients in DN group with that in diabeteic group, CRP was significantly higher. Chemerin level in the diabetic group and DN group is higher than control group. When comparing the patients in DN group with those in diabeteic group, serum level of chemerin was significantly higher. Serum level of chemerin is negatively correlated with HDL-C and positively correlated with FPG, HbA1c, LDL-C, BUN and Scr. Serum CRP is negatively correlated with HDL-C and positively correlated with FPG, HbA1c, LDL-C, BUN and Scr. Serum level of chemerin is positively correlated with CRP (r=0.701, P<0.05). CRP and chemerin of the DN patients rose significantly, and may participate in the occurrence and development of DN.
3
Publication available in full text mode
Content available

Serum omentin-1 and chemerin concentrations in pancreatic cancer and chronic pancreatitis

75%
Kiczmer P., Szydło B., Prawdzic Seńkowska A., Jopek J., Wiewióra M., Piecuch J., Ostrowska Z., Świętochowska E.
Folia Medica Cracoviensia
|
2018
|
vol. 58
|
issue 2
4
Publication available in full text mode
Content available

Serum and salivary chemerin concentrations in patients with colorectal cancer and obesity

63%
Waniczek D., Świętochowska E., Lorenc Z.
Annales Academiae Medicae Silesiensis
|
2021
|
issue 75
11-17
EN
INTRODUCTION: Chemerin is an adipokine, whose pro-inflammatory and carcinogenesis-related properties have recently been emphasized. The aim of this study was to examine the concentrations of chemerin in the serum and saliva of healthy subjects and patients with colorectal cancer (CRC) in II and III stage of TNM (tumor, node, metastasis) classification as well as to assess the relationship between the results and the clinical and pathological parameters. MATERIAL AND METHODS: 52 persons were qualified to the study, divided into two equal groups – control and study with cancer in stage II N0 and in stage III N+ according to TNM classification. Inside the groups, subgroups of persons with normal body weight 18.5 ≤ BMI < 25 and obese and overweight persons with a BMI ≥ 25 were distinguished. Serum and saliva chemerin concentrations were determined by immunoenzymatic methods. RESULTS: The median concentrations of chemerin were significantly higher in the study group as compared to the control group both in serum (384.36 ng/ml vs. 170.53 ng/ml) and saliva (15.45 ng/ml vs. 4.57 ng/ml; p < 0.0001). In the subgroups with a BMI above and below 25, we found no significant differences in the concentrations of chemerin either group. There were no significant differences in the levels of chemerin in the serum or saliva between stage II and III stage of TNM (p = 0.82 and p = 0.52). CONCLUSIONS: The assessment of serum and saliva chemerin concentrations in patients with CRC suggests that chemerin may be a valuable biomarker for early diagnosis of CRC. The influence of BMI on the results seems to be insignificant in patients with CRC. It seems that in some cases an easily accepted saliva test can replace a serum one.
PL
WSTĘP: Chemeryna jest hormonem wydzielanym przez adipocyty. W ostatnim czasie zwraca się uwagę na jej właściwości prozapalne i związane z karcynogenezą. Celem pracy było zbadanie stężeń chemeryny w surowicy i ślinie osób zdrowych oraz chorych z rakiem jelita grubego (RJG) w II i III stopniu zawansowania według klasyfikacji TNM (tumor, node, metastasis), a także ocena związku uzyskanych wartości z otyłością oraz wybranymi parametrami kliniczno-patologicznymi. MATERIAŁ I METODY: Do badania zakwalifikowano 52 osoby, które podzielono na dwie równe grupy – kontrolną i badaną z nowotworem w II stopniu zaawansowania z cechą N0 oraz w III stopniu z cechą N+ według klasyfikacji TNM. Wewnątrz grup wyróżniono podgrupy osób o prawidłowej masie ciała (18,5 ≤ BMI < 25) oraz osoby otyłe i z nadwagą (BMI ≥ 25). Stężenia chemeryny w surowicy i ślinie oznaczano metodami immunoenzymatycznymi. WYNIKI: Mediany stężeń chemeryny były istotnie wyższe w grupie badanej w porównaniu z grupą kontrolną, zarówno w surowicy (384,36 ng/ml wobec 170,53 ng/ml), jak i ślinie (15,45 ng/ml wobec 4,57 ng/ml; p < 0,0001). W żadnej grupie w podgrupach z BMI powyżej i poniżej 25 nie znaleziono istotnych różnic w stężeniach badanej adipokininy. Nie odnotowano również istotnych różnic stężeń chemeryny w surowicy i ślinie między nowotworami w II i III stopniu zaawansowania TNM (p = 0,82 i p = 0,52). WNIOSKI: Ocena stężeń chemeryny w surowicy i ślinie u pacjentów z RJG sugeruje, że badana adipokina może być cennym biomarkerem wczesnej diagnostyki tego nowotworu. Wpływ BMI na uzyskane wyniki stężeń w surowicy i ślinie wydaje się nieistotny u chorych z RJG. Wydaje się, że w pewnych przypadkach łatwo akceptowane przez chorych badanie śliny może zastąpić badanie surowicy.
5
Publication available in full text mode
Content available

Plejotropowe działanie chemeryny – białkowego produktu genu TIG2

63%
Chyra A.
Annales Academiae Medicae Silesiensis
|
2012
|
vol. 66
|
issue 2
55-58
EN
Increasing experimental evidence indicates that several factors that play a role in the immune response also infl uence metabolism. The immune response and metabolic regulation are highly integrated and interdependent. Chemerin was recently shown to be one of them. Chemerin is the only known protein ligand for a CKMLR1 receptor (chemokine like receptor 1), which is selectively expressed on some cells of the immune system. Chemerin is secreted as an inactive form and undergoes activa-tion through C-terminal cleavage primarily by serine proteases of the infl ammatory and coagulation cascades. There are at least two known active chemerin cleavage products: serum form (S form) without 9aa on the C-terminus and sspB form that lacks 6 C-terminal amino acids. Both truncated forms are potent chemoattractants for plasmacytoid dendritic cells and macrophages. Beside linking adaptive and innate immunity, chemerin has been recently added to the growing list of adipokines. The data indicate that this chemoattractant aff ects adipocyte diff erentation and metabolism.
PL
Odpowiedź immunologiczna organizmu oraz regulacja metabolizmu wykazują wiele wzajemnych zależności. Jednym z czynników pośredniczących w tych powiązaniach jest chemeryna – jedyny białkowy ligand receptora CMKLR1, występujący na powierzchni niektórych komórek układu odpornościowego. Chemeryna jest syntetyzowana w postaci nieaktywnej formy, która ulega aktywacji pod wpływem hydrolizy wiązania peptydowego dokonywanego przez peptydazy. Generowane w ten sposób formy S (pozbawiona 9-aminokwasów na C-końcu) i sspB (pozbawiona 6 aminokwasów na C-końcu) charakteryzują się aktywnością chemotaktyczną wobec plazmacytoidalnych komórek dendrytycznych i makrofagów. Chemeryna wpływa na rozwój odpowiedzi immunologicznej, stanowiąc swoiste ogniwo między odpornością wrodzoną i nabytą. Najnowsze badania pozwalają sądzić, że spektrum działania tej cząsteczki jest znacznie szersze. Chemerynę zaklasyfi kowano bowiem do wciąż rosnącej rodziny adipokin. Udowodniono, że wpływa ona także na różnicowanie komórek tłuszczowych oraz na modulację profi lu ekspresji genów zaangażowanych w ich metabolizm.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.